Erlotinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8784 publications

Machine learning prognostic model and drug survival analysis for lung adenocarcinoma in the context of radiotherapy.

Machine learning prognostic model and drug survival analysis for lung adenocarcinoma in the context of radiotherapy.

Journal: Pakistan journal of pharmaceutical sciences

Published: September 08, 2026

JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3-Survivin Axis.

JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3-Survivin Axis.

Journal: Integrative cancer therapies

Published: August 04, 2026

Retraction Notice to: Knockdown of the DJ-1 (PARK7) gene sensitizes pancreatic cancer to erlotinib inhibition.

Retraction Notice to: Knockdown of the DJ-1 (PARK7) gene sensitizes pancreatic cancer to erlotinib inhibition.

Journal: Molecular therapy. Oncology

Published: August 02, 2026

Retraction notice to "Correlation between TCF7 and bladder cancer and feasibility of Erlotinib targeting in bladder cancer: Molecular mechanism and expression of TCF7 recombinant protein" [Int. J. Biol. Macromol. 301 (2025) 140438].

Retraction notice to "Correlation between TCF7 and bladder cancer and feasibility of Erlotinib targeting in bladder cancer: Molecular mechanism and expression of TCF7 recombinant protein" [Int. J. Biol. Macromol. 301 (2025) 140438].

Journal: International journal of biological macromolecules

Published: July 30, 2026

Allosteric co-binding restores tyrosine kinase inhibitor affinity in T790M-mutant EGFR through conformational reprogramming.

Allosteric co-binding restores tyrosine kinase inhibitor affinity in T790M-mutant EGFR through conformational reprogramming.

Journal: Journal of biomolecular structure & dynamics

Published: July 29, 2026

Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors.

Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors.

Journal: Bioorganic chemistry

Published: July 24, 2026

Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.

Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 15, 2026

Integrated bulk, single-cell and spatial transcriptomic analyses identify KIFC1 as a driver of malignant progression in lung adenocarcinoma.

Integrated bulk, single-cell and spatial transcriptomic analyses identify KIFC1 as a driver of malignant progression in lung adenocarcinoma.

Journal: Molecular biology reports

Published: July 14, 2026

Erlotinib impairs epidermal tight junction and barrier integrity by inhibiting EGFR and Src and affects maturation of cell-cell junctions in human and mouse keratinocytes.

Erlotinib impairs epidermal tight junction and barrier integrity by inhibiting EGFR and Src and affects maturation of cell-cell junctions in human and mouse keratinocytes.

Journal: Tissue barriers

Published: July 13, 2026

Biosimilar Nivolumab-Based Combination Therapy in Advanced Oral Cavity Squamous Cell Carcinoma: A Real-World Case Series of Five Patients.

Biosimilar Nivolumab-Based Combination Therapy in Advanced Oral Cavity Squamous Cell Carcinoma: A Real-World Case Series of Five Patients.

Journal: Cureus

Published: July 06, 2026

Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy.

Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 22, 2026

Harnessing Box-Behnken design to optimize erlotinib-niclosamide co-loaded liposomes, overcoming EGFR-mutated lung cancer resistance, and improving sensitivity via EGFR/STAT3 signaling pathway.

Harnessing Box-Behnken design to optimize erlotinib-niclosamide co-loaded liposomes, overcoming EGFR-mutated lung cancer resistance, and improving sensitivity via EGFR/STAT3 signaling pathway.

Journal: Journal of liposome research

Published: June 22, 2026

Showing 1-12 of 8,784

Last Updated: 09/26/2026